Reishi, Homocysteine, and Cardiovascular Risk: The Evidence

Reishi and Cardiovascular Health

0 direct studies

No published trial has ever measured what reishi does to plasma homocysteine. The case that it might rests on three indirect routes — B vitamins, antioxidant activity, and anti-inflammatory activity. This article follows each one to the point where the evidence actually stops.

Jafari et al., Food Science & Nutrition, 2025

0

reishi trials that have measured plasma homocysteine, including the 17 pooled by Jafari 2025

5.7%

of the daily B6 requirement supplied even at the highest reishi dose used in any trial

Very low

GRADE certainty Jafari 2025 assigns to every outcome it pooled, positive findings included

Jafari et al., Food Science & Nutrition, 2025

View as image ↗

Homocysteine is not as well known as cholesterol, but elevated blood levels of this amino acid are an established cardiovascular risk factor in their own right.^[1] Reishi mushroom and homocysteine have not been studied together directly: no published clinical trial or animal study has measured reishi supplementation's effect on plasma homocysteine levels. That research gap is real, and this article states it at the start.

What reishi does have is a documented nutrient profile that includes several B vitamins, among them B6 — a cofactor for one of the two routes the body uses to clear homocysteine from the blood.^[3] It also has antioxidant and anti-inflammatory activity in preclinical models, targeting some of the same vascular damage pathways that elevated homocysteine activates.

Those are three separate arguments, and they are not equally strong. This article explains what homocysteine is, follows each of the three routes to the point where its evidence stops, and does the arithmetic that the B vitamin argument requires but rarely receives.

Homocysteine: The Cardiovascular Risk Factor Your Doctor May Not Mention

Homocysteine is produced naturally as a byproduct of breaking down methionine, an amino acid found in protein-rich foods. It sits at the centre of one-carbon metabolism, the network of reactions that also governs DNA methylation and the supply of methyl groups throughout the body.^[1]

When both routes work, homocysteine stays low; a threshold in the region of 10 to 15 micromoles per litre is commonly used to flag elevated levels, though laboratory cut-offs vary. When the routes are impaired — by B vitamin deficiency, genetic variants, or kidney disease — homocysteine accumulates, a state called hyperhomocysteinemia.

The damage is not hypothetical. Disruptions of this system are linked to vascular disease through effects on gene expression, endothelial integrity, lipid metabolism, and inflammatory pathways — mechanisms that connect elevated homocysteine to atherosclerosis and hypertension.^[1] B vitamin deficiency drives the same triad — hyperhomocysteinemia, oxidative stress, and endothelial dysfunction — which is how the nutritional and vascular stories became one story.^[2]

There is an important complication. Observational studies consistently associate low B vitamin status with higher cardiovascular risk, but randomised trials that supplement B vitamins have produced only modest reductions in major events.^[2] Homocysteine falls; event rates do not reliably follow. The field's current answer is that response depends on who is being treated — functional biomarkers and gene–nutrient interactions, particularly folate and riboflavin acting on MTHFR variants, separate the people who benefit from those who do not.^[2]

That nuance matters here, because it sets a ceiling on the whole question. Even a supplement that genuinely lowered homocysteine would not automatically lower cardiovascular risk.

The B Vitamin Connection: Where Reishi Enters, and How Far It Gets

Reishi's vitamin profile is documented. A 2022 review by El Sheikha in Foods compiles the composition of Ganoderma lucidum and reports, per 100 g of mushroom: thiamine (B1) 3.49 mg, riboflavin (B2) 17.10 mg, niacin (B3) 61.9 mg, and pyridoxine (B6) 0.71 mg, alongside minerals including iron (2.22 mg), calcium (1.88 mg), and zinc (0.70 mg).^[3]

Two features of that list matter more than the numbers themselves.

First, B6 is present — and B6 is the transsulfuration cofactor. That is a genuine point of contact with homocysteine metabolism, and it is the entire basis of the B vitamin argument.

Second, folate and B12 are absent from the profile. Neither appears in the composition table.^[3] Those are the two vitamins the remethylation route depends on, and they are also the ones most often deficient in hyperhomocysteinemia. So even taken at face value, reishi's vitamin profile addresses one of the two exits and leaves the other untouched.

But the profile should not be taken at face value, because of the units.

The B6 Arithmetic

Reishi Contains B6. A Reishi Dose Does Not.

The composition figure everyone quotes — 0.71 mg of B6 — is measured per 100 grams of mushroom. Reishi is not eaten in 100-gram servings; it is taken in doses that the clinical trials put between 200 and 11,200 mg a day. Convert the one to the other and the B-vitamin route to homocysteine closes almost entirely.

Composition from El Sheikha 2022, Table 2 [3]; dose range from the 17 trials pooled by Jafari 2025 [8]. The conversion is arithmetic, not an effect estimate. Two things push the real figure lower still: these values are for whole mushroom, while most products are water or ethanol extracts that are not made to carry B vitamins across — and no study has measured the B6 content of a finished reishi extract.

Unit conversion of refs [3] and [8] (see references)

The composition figure is reported per 100 grams of mushroom. Nobody consumes reishi that way — it is a woody, bitter polypore taken as a capsule, powder, or extract. The 17 randomised trials pooled in the most recent meta-analysis used doses between 200 and 11,200 mg per day.^[8] Converting the composition figure to those doses, reishi supplies between 0.0014 mg and 0.080 mg of B6 per day — roughly 0.1% to 5.7% of the 1.4 mg adult requirement.

Set against the doses used in trials that actually lower homocysteine, typically B6 in the tens of milligrams per day, reishi at its highest-ever trial dose provides on the order of 0.16% of a therapeutic dose. And that is a generous upper bound: these are whole-mushroom values, while most commercial products are hot-water or ethanol extracts, which are formulated to concentrate polysaccharides and triterpenes, not to carry water-soluble vitamins across. No study has measured the B6 content of a finished reishi extract.

Claim Check

The B Vitamin Shortcut

The claim

“Reishi contains B vitamins that clear homocysteine, so reishi should help lower homocysteine.”

Composition tables reporting per-100-gram vitamin content, quoted without converting to an actual supplement dose.

What research shows

Unsupported

Reishi does contain B6, the transsulfuration cofactor. But the amount delivered at real doses is a rounding error against the daily requirement — under 6% at the highest dose used in any clinical trial, and a fraction of a percent of a therapeutic B6 dose.

The profile also lists no folate and no B12, the two vitamins the other clearance route depends on. Reishi is not a meaningful B vitamin source at the doses people take, and no trial has tested the claim directly.

El Sheikha 2022 composition data [3]; dose range from Jafari 2025 [8]

The honest version of the B vitamin observation is narrow: reishi is not nutritionally disconnected from homocysteine metabolism. That is a different statement from the claim that reishi affects homocysteine, and the arithmetic does not support the stronger one.

The Oxidative Route: Real Antioxidant Activity, Tested on the Wrong Target

The second argument bypasses vitamins entirely. Elevated homocysteine contributes to vascular damage partly through oxidative stress, and oxidised LDL is a well-established driver of atherosclerotic plaque.^[1][6] If reishi blunts oxidative damage, the reasoning goes, it should blunt this part of homocysteine's effect too.

Reishi's antioxidant activity is genuinely documented — though the work that establishes it sits in animals and test tubes.^[5]

Preclinical Evidence

Rahman, Abdullah & Aminudin (2018) · International Journal of Medicinal Mushrooms

Population

Rats fed Ganoderma lucidum hot-water extract, plus a battery of in vitro assays

Intervention

Hot-water extract at 200 mg/kg body weight, and five solvent-partitioned fractions

Finding

At 200 mg/kg the extract lowered plasma total cholesterol, triacylglycerol and LDL cholesterol and raised HDL cholesterol. Separately, in vitro assays showed inhibition of human LDL oxidation and lipid peroxidation, and antioxidant enzyme activity (catalase, glutathione peroxidase, superoxide dismutase) was measured in the plasma and liver of extract-fed rats.

narrow-scope An animal and in vitro study of lipids and oxidative stress. Homocysteine was not measured, and the LDL-oxidation result comes from a test tube, not a living animal.

Rahman et al., Int J Med Mushrooms, 2018 [5]

A 2024 review in Heliyon on Ganoderma lucidum polysaccharides and atherosclerosis adds the mechanistic layer: these polysaccharides activate the Nrf2/HO-1 pathway, the cellular defence system that switches on antioxidant genes in response to oxidative stress. The primary evidence the review cites for that pathway is a mouse study in which a high dose of polysaccharide (400 mg/kg) reduced lipids and upregulated antioxidant enzymes in a diabetic model.^[6]

That last point is the limit of this route. The reishi studies establishing antioxidant effects were testing oxidative stress from other sources, in rodents and cell cultures. The pathways overlap with those homocysteine activates, but reishi has never been tested in a homocysteine-specific context. The review's own summary is that most anti-atherosclerosis work on these polysaccharides remains in animal models and the clinical application is still to be established.^[6]

The Inflammatory Route: Genuine Mechanistic Overlap, No Human Test

The third argument runs through inflammation. Elevated homocysteine feeds inflammatory signalling in vascular tissue, and inflammatory pathways are central to plaque progression.^[1]

Reishi acts on the same machinery. A 2014 review by Bhardwaj and colleagues in Recent Patents on Inflammation & Allergy Drug Discovery surveys the molecular mechanisms behind Ganoderma lucidum's suppression of inflammatory and allergic responses, noting the mushroom's capacity to target inflammatory cytokines.^[7] The Heliyon review documents the specific axis in a cardiovascular context: TLR4/NF-κB signalling driving TNF-α, IL-1β, and IL-6, with reishi polysaccharides acting against it.^[6]

This is a real mechanistic intersection: the inflammatory pathways elevated homocysteine activates and the ones reishi compounds suppress are the same pathways. It does not follow that reishi counteracts homocysteine-induced inflammation in people. That question has not been studied. What the overlap establishes is that the biological rationale for investigating it is not arbitrary.

Where Each Argument Stops

Three Routes to Homocysteine, None of Them Finished

Every case for reishi and homocysteine travels one of three routes. Run them along the same evidence track and the pattern is consistent: the mechanism rungs are occupied, the human rung is empty, and the rung that would actually settle the question — homocysteine measured in people — has never been reached by any route.

A filled cell means published evidence exists at that tier for that route — not that the route works. The three routes are real biology; what the map shows is that none of them has been carried to the endpoint the question is actually about.

Evidence synthesis; tiers from refs [3], [5]–[8] (see references)

For a related look at how a different mushroom compound addresses the same oxidative and inflammatory pathways in cardiovascular disease, see Ergothioneine and Cardiovascular Disease: The Mushroom-Exclusive Antioxidant. Reishi also contains ergothioneine, and that compound's relationship to arterial oxidative stress is covered in Ergothioneine and Atherosclerosis Prevention.

What the Human Evidence Shows, and What It Cannot Show

The broadest human read on reishi is a 2025 GRADE-assessed systematic review and meta-analysis by Jafari and colleagues in Food Science and Nutrition, pooling 17 randomised controlled trials and 971 participants across doses of 200 to 11,200 mg/day for one to 24 weeks.^[8]

The Human Ceiling

Four Findings, Seven Nulls, and One Rating That Covers Them All

Jafari 2025 is the most rigorous human read on reishi available — 17 randomized trials, 971 participants. Its four positive results get quoted often. The sentence that governs all of them, including the positives, gets quoted far less: the certainty of the evidence was rated very low across every outcome.

All values as reported by Jafari 2025 [8]. WMD = weighted mean difference. Subgroup analyses found additional improvements in BMI, total cholesterol, creatinine and MDA in specific strata — lower doses (<1,400 mg/day) and participants under 50 — but those are subgroup findings carrying the same very-low certainty.

All figures from ref [8] (see references)

Two things follow from that ledger, and the second is usually left out.

The first is the absence: plasma homocysteine was not an outcome in any of the 17 trials. It has not been measured in any published reishi clinical trial. The most important direct question has never been asked in a human setting.

The second is the certainty rating. Jafari and colleagues rated the quality of evidence very low across all outcomes.^[8] That applies to the four significant findings as much as to the null ones. A very low GRADE rating means the true effect is likely to differ substantially from the pooled estimate — so the BMI, creatinine, GPx, and heart-rate results are low-confidence signals awaiting replication, not established properties of reishi. Citing this meta-analysis as evidence that reishi "does something" while omitting its certainty rating misrepresents it.

This is consistent with the wider literature. A 2021 review in Pharmaceutical Biology covering reishi and cardiometabolic risk found that in vitro and animal work shows antioxidative, antihypertensive, hypoglycaemic, lipid-lowering, and anti-inflammatory properties, but that health benefits in clinical trials are inconsistent — attributing the inconsistency to differing formulations and study populations, and calling for large controlled trials of standardised preparations.^[4] Of the effects reviewed, the most compelling human evidence was for glucose lowering in type 2 diabetes, not for any cardiovascular endpoint.^[4]

Evidence Position

1. Cell studiesmissing

   No cell work has tested reishi against homocysteine-induced endothelial or oxidative damage.

2. Animal studiesmissing

   No animal study has measured plasma homocysteine after reishi administration.

3. Small human trialsmissing

   Homocysteine has never been an endpoint in a reishi trial.

4. Large RCTsmissing

   None.

5. Meta-analysismissing

   Jafari 2025 pooled 17 reishi RCTs; homocysteine was not among the outcomes.

Every rung is empty. This is not weak evidence or mixed evidence — it is an untested hypothesis. What exists is adjacent evidence on other endpoints, which cannot be substituted for the missing measurement.

Absence confirmed against the 17 trials pooled in Jafari 2025 [8]

Research Gap

Closing the Question

What would it take to actually know whether reishi affects homocysteine?

○

Measure plasma homocysteine in a reishi trial

The single cheapest fix: homocysteine is a routine, inexpensive assay that could be added as a secondary endpoint to any existing reishi protocol.

○

Characterise the B vitamin content of finished extracts

Composition data exists for whole mushroom only. Nobody has measured what survives into a commercial hot-water or ethanol extract.

○

Enrol a population with elevated homocysteine

Trials in healthy participants cannot show a lowering effect, because there is little to lower. Baseline hyperhomocysteinemia is required.

○

Test against homocysteine-induced damage specifically

The Nrf2/HO-1 and NF-κB work uses other oxidative and inflammatory stressors. A homocysteine challenge model would test the actual claim.

○

Use a standardised preparation

Chan 2021 attributes much of the clinical inconsistency to varying formulations; a homocysteine trial would inherit that problem unless the preparation is characterised.

No registered trial currently lists homocysteine as a reishi endpoint.·A secondary-endpoint addition could report within a single trial cycle; a dedicated trial in a hyperhomocysteinemic population is a multi-year undertaking.

Gap analysis against refs [3]–[8]

Clinical Context

Moderate

Elevated Homocysteine Is a Medical Finding, Not a Supplement Problem

Concern

Treating a raised homocysteine result with reishi — or with any supplement chosen for its mechanism rather than its evidence — risks leaving a treatable cause unaddressed. Hyperhomocysteinemia can reflect B12 or folate deficiency, kidney disease, or genetic variants such as MTHFR polymorphisms, each of which calls for a different response.

What the research says

Elevated homocysteine should be evaluated and managed by a clinician, who can identify the underlying cause and use the B vitamins that have actually been trialled for it. Reishi has no evidence base for this use at all.

Particularly relevant for: Anyone with a raised homocysteine result, known cardiovascular disease, kidney impairment, or B12 or folate deficiency.

What to do

Discuss any reishi supplementation with your doctor, particularly alongside anticoagulant, antiplatelet, antihypertensive, or glucose-lowering medication — reishi has documented hypoglycaemic and blood-pressure-relevant activity in preclinical work.

Clinical context from Al Qassab 2026 [1] and Awashra 2026 [2]

Where This Leaves the Question

What the available data supports is a reasonable biological rationale for investigation: reishi contains B6, and it has antioxidant and anti-inflammatory activity in preclinical models that touches pathways relevant to homocysteine-driven vascular damage.

What the data does not support is any claim that reishi lowers homocysteine or reduces homocysteine-associated cardiovascular risk. The B vitamin route fails on dose arithmetic before it reaches the question of efficacy. The antioxidant and inflammatory routes stop at rodents and cell cultures. The human trial literature has never measured the outcome, and what it has measured, it measured at very low certainty.

That is not a reason to dismiss the question — it is a reason to keep it open and unanswered rather than filling it with mechanism. Reishi may yet prove to have cardiovascular value through routes that have nothing to do with homocysteine. But on this specific question, the correct answer is that nobody has looked.

This article is educational and is not medical advice.

For the sibling articles in this cluster, see Reishi and Cholesterol: Does It Lower LDL? and Reishi and Blood Pressure: Mechanisms and Evidence, which cover the cardiovascular markers that have been directly tested in reishi clinical trials. For the atherosclerosis angle, see Ganoderma lucidum and Atherosclerosis Prevention. For the broader cardiovascular picture, see Reishi and Heart Health: Cardiovascular Research Review, and for an introduction to the mushroom itself, What Is Reishi Mushroom: The Science Behind the Mushroom of Immortality.

The Bottom Line

No study has directly measured reishi's effect on plasma homocysteine. Three indirect arguments exist, and each stops short. The B vitamin route is real but fails on arithmetic: reishi's documented B6 content is reported per 100 g of mushroom, and at the highest dose used in any clinical trial it supplies about 5.7% of the daily B6 requirement and a fraction of a percent of a therapeutic dose — while folate and B12, the vitamins the other clearance route needs, are absent from the profile entirely. The antioxidant route (Nrf2/HO-1) and the anti-inflammatory route (NF-κB) are genuine mechanistic overlaps but are established in rodents and cell cultures that were not testing homocysteine. The largest human meta-analysis (Jafari 2025) found no effect on blood pressure, lipids, glucose, or inflammatory markers, never measured homocysteine, and rated its evidence very low certainty across every outcome. The rationale for studying this is real; the research does not exist.

Frequently Asked Questions

What is homocysteine and why is it a cardiovascular risk factor?

Homocysteine is an amino acid produced as a byproduct of metabolising methionine, a protein building block. When elevated in the blood, it is associated with endothelial dysfunction, oxidative stress, disturbed lipid metabolism, and inflammatory signalling — mechanisms that connect it to atherosclerosis and hypertension. These effects are considered separate from LDL cholesterol, which is why elevated homocysteine is treated as an independent risk factor. Levels around 10 to 15 micromoles per litre are commonly used as a flag, though laboratory cut-offs vary. The body clears homocysteine through two routes that require B6, B12, and folate.

Does reishi lower homocysteine?

There is no published study, clinical or animal, measuring reishi's effect on plasma homocysteine. The honest answer is that it has not been tested. Reishi does contain B6, a cofactor for one of the two clearance routes, but the amount delivered at realistic doses is very small — under 6% of the daily requirement even at the highest dose used in any clinical trial. Reishi also has antioxidant and anti-inflammatory activity on pathways that elevated homocysteine affects, but only in rodent and cell studies that were not measuring homocysteine.

Can mushrooms reduce homocysteine levels?

No controlled study has tested any mushroom species' direct effect on plasma homocysteine. Mushrooms are generally reasonable dietary sources of B vitamins, and B vitamins — particularly B6, B12, and folate — are the tools used clinically to lower elevated homocysteine. Reishi's documented profile includes B1, B2, B3, and B6, but not folate or B12. The more important limitation is quantity: composition figures are reported per 100 grams of mushroom, while reishi is taken in gram or sub-gram doses, so the B vitamin contribution at real doses is negligible compared with the doses used in homocysteine-lowering trials.

What supplements lower homocysteine?

The supplements with the strongest evidence are B6, B9 (folate), and B12, the cofactors for the two routes that clear homocysteine. Clinical trials using B vitamin combinations do reduce plasma homocysteine. Importantly, though, randomised trials of B vitamin supplementation have produced only modest reductions in cardiovascular events, and which individuals benefit appears to depend on functional vitamin status and genetic factors such as MTHFR variants. Lowering the number does not automatically lower the risk. Reishi has not been studied as a homocysteine-lowering supplement. Anyone considering supplementation for elevated homocysteine should do so with a clinician rather than self-treating.

Is homocysteine more important than cholesterol for heart disease?

Both are cardiovascular risk factors, but the evidence for each is at a different stage. Elevated LDL cholesterol has exceptionally strong trial evidence linking it to cardiovascular events, and lowering it with statins reduces those events. Homocysteine has consistent associations with cardiovascular disease and well-characterised damage mechanisms, but trials that lower it with B vitamins have not delivered proportionate reductions in events. Most clinicians therefore treat LDL as the more established target while monitoring homocysteine in specific situations — unexplained atherosclerosis, recurrent events, or risk of B12 or folate deficiency.

Sources & References

1. 1RTHM-02421·Al Qassab, Mohamad et al. (2026). “One-carbon metabolism and cardiovascular disease: Molecular mechanisms, genetic influences, and epigenetic regulation..” Biochemistry and biophysics reports.Study breakdown →PubMed →↩
2. 2RTHM-02420·Awashra, Ameer et al. (2026). “B vitamins and cardiovascular health: mechanisms, clinical evidence, and precision prevention strategies..” Nutrition & metabolism.Study breakdown →PubMed →↩
3. 3RTHM-02419·El Sheikha, Aly Farag (2022). “Nutritional Profile and Health Benefits of Ganoderma lucidum "Lingzhi, Reishi, or Mannentake" as Functional Foods: Current Scenario and Future Perspectives..” Foods (Basel.Study breakdown →PubMed →↩
4. 4RTHM-01332·Chan, Sze Wa et al. (2021). “The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk..” Pharmaceutical biology.Study breakdown →PubMed →↩
5. 5RTHM-00997·Rahman, Mohammad Azizur et al. (2018). “Evaluation of the Antioxidative and Hypo-cholesterolemic Effects of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), in Ameliorating Cardiovascular Disease..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
6. 6RTHM-01944·Ma, YiZheng et al. (2024). “Research progress of Ganoderma lucidum polysaccharide in prevention and treatment of Atherosclerosis..” Heliyon.Study breakdown →PubMed →↩
7. 7RTHM-00578·Bhardwaj, Neha et al. (2014). “Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum..” Recent patents on inflammation & allergy drug discovery.Study breakdown →PubMed →↩
8. 8RTHM-02098·Jafari, Ali et al. (2025). “The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials..” Food science & nutrition.Study breakdown →PubMed →↩